Developing a Smartphone Application That Promotes Responsible Short-Acting Beta2-Agonist Use in People with Asthma: A Participatory Design

Around 339 million people worldwide have asthma, and 50% have uncontrolled asthma. One trait of uncontrolled asthma, often seen in primary care, is short-acting β2-agonist (SABA) overuse, defined as using SABA more than twice a week. SABA overuse can cause adverse health effects. An application coul...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Berg, Liselot N., Hallensleben, Cynthia, Chavannes, Niels H., Versluis, Anke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318130/
https://www.ncbi.nlm.nih.gov/pubmed/35886348
http://dx.doi.org/10.3390/ijerph19148496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318130/
https://www.ncbi.nlm.nih.gov/pubmed/35886348
http://dx.doi.org/10.3390/ijerph19148496

Ejemplares similares